- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review ; volume:38 ; number:7 ; day:8 ; month:6 ; year:2021 ; pages:3674-3693 ; date:7.2021
Advances in therapy ; 38, Heft 7 (8.6.2021), 3674-3693, 7.2021
- Urheber
-
Arru, Caterina
Miglio, Maria Rosaria De
Cossu, Antonio
Muroni, Maria Rosaria
Carru, Ciriaco
Zinellu, Angelo
Paliogiannis, Panagiotis
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-021-01796-6
- URN
-
urn:nbn:de:101:1-2021101719323592456197
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Arru, Caterina
- Miglio, Maria Rosaria De
- Cossu, Antonio
- Muroni, Maria Rosaria
- Carru, Ciriaco
- Zinellu, Angelo
- Paliogiannis, Panagiotis
- SpringerLink (Online service)
Ähnliche Objekte (12)
Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
Arzneimittel Profil Durvalumab
Flexibler Einsatz von Durvalumab plus Chemotherapie beim fortgeschrittenen kleinzelligen Lungenkarzinom
Radiotherapie plus Durvalumab beim lokal fortgeschrittenen NSCLC: die DOLPHIN-Studie
Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma
Retinal Vasculitis Secondary to Durvalumab
Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial
Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
Arzneimittel Profil Durvalumab
Flexibler Einsatz von Durvalumab plus Chemotherapie beim fortgeschrittenen kleinzelligen Lungenkarzinom
Radiotherapie plus Durvalumab beim lokal fortgeschrittenen NSCLC: die DOLPHIN-Studie
Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma
Retinal Vasculitis Secondary to Durvalumab
Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial
Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
Arzneimittel Profil Durvalumab
Flexibler Einsatz von Durvalumab plus Chemotherapie beim fortgeschrittenen kleinzelligen Lungenkarzinom
Radiotherapie plus Durvalumab beim lokal fortgeschrittenen NSCLC: die DOLPHIN-Studie
Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma
Retinal Vasculitis Secondary to Durvalumab
Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial